Dose reduction or withdrawal of the drug, although in a limited number of patients, did not allow long-lasting increase of the T-cell subset to values comparable to those of CTRLs, suggesting that the effect of the drug on Tregs is not reversible upon its withdrawal. Up to now, only the report by Murawsky et al. 12 has shown that the incubation of Tregs with the JAK2/3 inhibitor AG-490 significantly reduced both the percentage and the mean fluorescence intensity of FOXP3 þ Tregs in vitro, likely by blocking of the JAK/STAT5 pathway that is crucial for Treg development, survival and proliferation. 13 Although our study was performed ex vivo, and ruxolitinib is a JAK1/2 inhibitor, the data reported by Murawski et al. strongly indicate a specific effect of ruxolitinib on Tregs. In this regard, it is likely that also other JAK inhibitor molecules could exert a similar effect on this cell subset. 14, 15 Our results can have important clinical implications. Tregs have been shown to suppress T-cell-mediated host immune responses against self/nonself antigens; in addition, a protective role for Tregs against specific viral pathogens (for example, herpes simplex virus 2, lymphocytic choriomeningitis virus, West Nile virus), some parasites and fungal pathogens (Plasmodium berghei, Toxoplasma gondii and Candida albicans) has been documented. 16 Thus, we argue that the severe reduction in circulating Tregs observed in our patients treated with ruxolitinib may count as a major cause of immune surveillance disruption in vivo, as recently described both in vivo and in vitro for dendritic cell differentiation and induction of antigen-specific T-cell responses, including viral clearance. 17 With regard to this important issue, however, the clinical consequences, if any, of a long-term therapy with ruxolitinib are still under evaluation. In our experience no specific disease, in particular with autoimmune implications, was evidenced in the studied patients. However, the increased frequency of infections, such as tubercolosis, herpes zoster or simplex infection/reactivation and pneumonia of suspected viral origin that we observed in our patients with MF receiving ruxolitinib, could be explained by the reduced levels of Tregs.
We consider the documented decrease of Treg cells in patients with MF undergoing therapy with ruxolitinib, an observation of special relevance since preparations of JAK inhibitors, including ruxolitinib, are emerging drugs that may have a broader range of therapeutic indications in the near future. (Figure 1a ). Of interest, p53 directly regulates the expression of the miR-34 family (miR-34a/b/c), and loss of miR-34 expression is linked to resistance against apoptosis induced by p53-activating agents used in chemotherapies. 2 To define that the Axl 3 0 -UTR is a functional target of miR-34a, we first performed in vitro luciferase reporter gene assays using the reporter construct containing the entire Axl 3 0 -UTR and increasing amounts of miR-34a mimic or sc-miR in HEK293 (human embryonic kidney 293) cells. A dose-dependent reduction of the luciferase activity was observed when the reporter gene and miR-34a mimic were co-transfected (Figure 1b, left panel) . As expected, miR-34a did not show any effect on the pMIR-lucAxl 3 0 -UTR ( À 110) reporter gene lacking the miR-34a-binding site (Figure 1b, right panel) . We also found that co-transfection of miR34a mimic with a plasmid DNA expressing the full-length Axl gene reduced Axl expression in a dose-dependent manner (Figure 1c ). In addition, enforced introduction of miR-34a mimic in primary CLL B cells reduced endogenous level of Axl (Figure 1d ). Taken together, these results suggest that miR-34a targets the Axl 3 0 -UTR and reduces Axl protein level. During progression of our study, 3 two independent groups of investigators have reported a similar complementary binding site for miR-34a in the Axl 3 0 -UTR; 4, 5 however, their findings were limited to established cell lines such that any clinical correlation was less obvious. These initial findings became of more clinical interest as miR34a, a direct target of p53, is reported to be associated with the adverse outcome in CLL patients.
CONFLICT OF INTEREST
6-8 Therefore, we interrogated whether enforced activation of p53 could reduce Axl expression in primary CLL B cells using a DNA-damaging agent, doxorubicin. Results demonstrated accumulation of p53 protein in doxorubicintreated CLL B cells from all the CLL patients tested (n ¼ 14) who had various chromosomal abnormalities detected by fluorescence in situ hybridization (FISH), albeit at variable degrees ( Figure 1e ). We noted that CLL B cells with deletion of 17p13 or 11q23 (11q23 defects: P6, P7; 17p13 defects: P8, P9) after doxorubicin exposure, accumulated lower levels of p53 and p21, the latter a direct target of p53, relative to the CLL clones with wild-type p53 or the ATM gene, an upstream regulator of p53 function (Figure 1e ). Consistent with p53 activation, substantial reduction of Axl expression on doxorubicin-treated CLL B cells was noted including the CLL clones with heterologous deletion of the p53 or ATM gene when compared with the untreated cells ( Figure 1f) . Next, to establish that it was the increased expression of miR-34a, which reduced Axl expression in doxorubicin-exposed CLL B cells, we measured the levels of mature miR-34a in these CLL B cells. Of note, CLL B cells do not express other members of the miR-34 family: miR-34b/c, 8 which recognize the same target binding sequence as does miR-34a. 2 An increase of mature miR-34a at variable levels was detected in doxorubicin-treated CLL B cells from different patients (Figure 1g ). Interestingly, leukemic B cells with 11q23/17p13 defects also showed variable degrees of miR34a upregulation in response to doxorubicin (Figure 1g ).
Multiple studies indicated that p53 could also be activated upon DNA damage independent of ATM via Atr, Chk2 or DNA-PK. 9, 10 This raised the possibility that p53 was likely to be activated in 11q23-defected CLL clones independent of ATM upon DNA damage. However, induction of p53 and increase of p21/miR-34a in 17p13-/11q23-defected CLL B cells in response to DNA damage is likely due to the presence of sub-population of cells without the indicated cytogenetic defects and/or these cells have retained one intact wild-type allele. To begin to explore the latter possibility, we sequenced the p53 gene (exons 4-9) in the leukemic B cells from the two 17p13-deleted patients (P8, P9). We found that P8 had a heterozygous splice mutation after exon 4 (GT-TT), although the precise proportion of CLL B cells that had only the heterozygous splice mutation was not known as only 42% of the CLL clone was 17p13 deleted. It is however likely that not all the CLL B cells have this defect as this patient showed activation of the p53 axis upon DNA damage (Figures 1e and g ). CLL B cells from P9 harbored splice mutations on the p53 gene before exon 5 (AG-AT and GG-T) after amino acid 153, resulting in a frameshift mutation with a relative abundance of B30% in the CLL B cells. This was estimated by relative sequence peak heights at the respective nucleotide positions. Of note, CLL B cells from P9 had functionally active p53 (Figures 1e and g ).
An alternative explanation for the differential levels of miR-34a in CLL B cells could be its promoter methylation status. 11, 12 The promoter region containing a p53-binding site and transcription start site of miR-34a gene has been mapped to 430 kb upstream of the mature miR-34a and is within a large (41.5 kb) CpG island. 13 Indeed, leukemic B cells from CLL patients (P1-P3, P5, P7) who had no 17p13 defects contained both methylated and unmethylated miR-34a promoters (Figure 1h, upper panel) . Interestingly, CLL B cells from patients (P10-P14) with no 17p13 defects exhibited predominantly unmethylated miR-34a promoter region except P13, where low-level methylation of the miR-34a promoter was evident (Figure 1h, lower panel) . However, CLL B cells from P9 with 17p13 defects had unmethylated miR-34a promoter only, whereas P8 had trace level of methylation and a dominant level of unmethylated miR-34a promoter region (Figure 1h, upper panel) . The high level of miR-34a in P9 (Figure 1g ) is therefore likely due to both the unmethylated status of miR-34a promoter region and that significant number of the CLL clones had wild-type p53. A relatively low level of miR-34a in P8 (Figure 1g ) could be explained by the presence of methylation in the promoter region and slightly higher numbers of 17p13-defective cells. Collectively, these findings suggest that epigenetic regulation of miR-34a expression contributes to the pathobiology of CLL B cells, independent of p53 status.
As fludarabine, a standard chemotherapeutic agent in CLL, is known to induce DNA damage, we were interested in knowing what the impact of this drug has on Axl expression in CLL B cells. Indeed, fludarabine treatment substantially reduced Axl expression on leukemic B cells from CLL patients (n ¼ 6) (Figure 1i ), likely due to activation of the p53/miR-34a axis in CLL B-cells (Figures 1j  and k) , suggesting that reduction of Axl expression could be another mechanism by which fludarabine reduces apoptotic resistance and/or induces apoptosis in CLL B cells.
Finally, we hypothesized that CLL B cells with 17p13 defects might express higher levels of Axl relative to those with no 0 -UTR. HEK293 cells were co-transfected with luciferase reporter plasmid DNAs containing the entire Axl 3 0 -UTR with a putative miR-34a-binding site (full-length) or without the miR-34a-binding site (Axl 3 0 -UTR ( À 110)) and increasing amounts of miR-34a mimic or sc-miR as control. After 24 h, luciferase activity was measured in the cell lysates. Experiments were repeated two times in triplicates. Data were normalized and presented as mean values with standard deviations. (c) Exogenous miR-34a reduces Axl expression. HEK293 cells were cotransfected with an Axl-expressing plasmid DNA containing the putative miR-34a-binding site in the 3 0 -UTR and increasing amounts of miR-34a or sc-miR for 24 h. Cells were examined for the expression of Axl by western blot using a specific antibody to Axl. Lamin B was used as a loading control. (d) Introduction of miR-34a mimic reduces Axl expression in primary CLL B cells. Purified CLL B cells were transfected with miR-34a mimic or sc-miR as control using B-cell-specific nucleofection reagent (Amaxa). After 24 h, cell lysates were analyzed for the expression of Axl by western blots using a specific antibody. Actin was used as a loading control. Representative result of CLL B cells from three different CLL patients is shown. (e) Doxorubicin activates p53. Lysates from purified CLL B cells treated with doxorubicin or left untreated for 16 h were analyzed for the expression of p53 and its downstream target p21 in western blots using specific antibodies. Actin was used as a loading control. CLL B cells from various CLL patients are indicated by arbitrary numbers (P1-P14). (f ) Impact of doxorubicin on Axl expression. CLL B cells from the same CLL patients' cohort (P1-P14) studied above (e) were treated with doxorubicin or left untreated for 16 h. Axl expression was determined by flow cytometry using a specific antibody. Percent of cells with FISH-detectable chromosomal abnormalities are indicated. (g) Doxorubicin treatment activates miR-34a expression in CLL B cells. Total RNA was extracted from untreated and doxorubicintreated CLL B cells and miR-34a levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) using primers specific for mature miR-34a and normalized using the 2 À DDCt method relative to U6-snRNA (RNU6B). Relative miR-34a expression levels in untreated vs doxorubicin-treated CLL B cells are presented as 'fold changes' determined as mean of triplicate values. CLL B cells studied here were chosen from the same cohort of CLL patients depicted and studied above in panels e and f. (h) Methylation-specific PCR analysis of the miR-34a promoter in CLL B cells. DNA isolated from purified CLL B cells of the CLL patients (P1-P3, P5, P7-P14) whose miR-34a levels were studied above (g) were subjected to bisulfite conversion and analyzed by methylation-specific PCR (MSP) with primers specific for methylated (M) and unmethylated (U) miR-34a promoter DNA. Amplified PCR products were run on a 1% agarose gel along with a standard DNA ladder (Invitrogen; 1st lane from left) to ascertain the size of the PCR products. (i) In vitro fludarabine treatment reduces Axl expression on CLL B cells. CLL B cells from CLL patients (P15-P20) were treated with fludarabine (F-ara-A) for 16 h or left untreated and Axl expression was determined by flow cytometry as described above. Doxorubicin was included as a positive control. (j) Fludarabine activates p53. Cell lysates prepared from untreated, doxorubicin-treated and F-ara-A-treated CLL B cells from CLL patients (P15-P20) were examined for the expression of p53 and p21 in western blot analysis. Actin was used as a loading control. (k) Fludarabine upregulates miR-34a expression. Total RNA was extracted from untreated, doxorubicin-treated and F-ara-A-treated CLL B cells from the same CLL patients used above (P15-P20). Mature miR-34a levels were measured by qRT-PCR and presented as 'fold changes' as described in panel g. detectable genetic abnormalities. Indeed, a significantly (Po0.0001) higher levels of Axl expression was detected on CLL B cells from the patients with 17p13 deletion as compared with those with no genetic abnormalities (Figure 2a, left panel) . In-depth analysis of the same 17p13 cohort shows that the CLL patients with 475% CLL B cells carrying 17p13 defects express significantly higher levels (Po0.002) of Axl compared with those patients having o75% leukemic B cells with 17p13 defects (Figure 2a, right panel) , further indicating that CLL patients with non-functional p53 may express higher levels of Axl. To pursue Axl as a therapeutic target in 17p13-deleted CLL patients, we observed that SGI-7079, a high-affinity Axl inhibitor (Tolero, Lehi, UT, USA), induces massive apoptosis in CLL B cells who had 17p13 deletion in at least 40% of leukemic B cells (n ¼ 15) (Figure 2b) . Interestingly, when we compared the sensitivity of the leukemic B cells with 17p13 defects vs no genetic abnormalities (normal FISH; n ¼ 10) to SGI-7079, no significant difference in LD 50 (lethal dose, 50%) doses was detected (Figures 2b and c) . Importantly, SGI-7079 induces apoptosis in CLL B cells likely by targeting Axl phosphorylation (Figure 2d ). However, we cannot completely rule out off-target effects of SGI-7079 on other RTKs. Collectively, these results suggest that Axl is a targetable RTK in CLL and provides a future therapeutic option for very 'high-risk' 14 CLL patients with non-functional p53.
In summary, we found that p53 activation negatively regulates Axl expression via upregulating miR-34a in CLL B cells with functional p53 (Figure 2e ). Although this study found an inverse link between p53 inactivation and Axl expression in CLL B cells, we are aware that Axl can also be regulated by other mechanisms including multiple transcription factors and/or epigenetic modulations. 15 However, our study uniquely adds to the growing body of literature regarding Axl regulation in human malignancies and suggests that p53 inactivation stabilizes Axl protein levels in CLL. Thus, Axl inhibition in CLL should be considered and evaluated as a potential therapy (Figure 2e ). 0 -UTR and inhibits its translation resulting in the reduction of Axl protein level. In CLL B cells with a non-functional p53 (due to chromosomal deletion and/or inactivating mutation on p53 gene), this regulatory pathway remains non-functional, which likely results in significant upregulation/stabilization of Axl RTK protein levels. Importantly, this study finds that Axl has the potential to be an effective therapeutic target in CLL B cells with or without a functional p53 gene.
